



CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 26, 2004

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG

METHODS (As Amended)

Group Art Unit: 1642

Examiner: Yaen, C.

Atty. Dkt. No.: 3999.002587

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the document listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the

receipt of a first Official Action reflecting an examination on the merits and hence is timely filed

in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection

herewith. Even if an Official Action had been issued in the last few days, no fees would be

required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed

on the accompanying Form PTO-1449 was not cited in a communication from a foreign patent

office in a counterpart foreign application. The listed document was published in October, 2004,

and has a face date of October 15, 2004, which is less than three months before the filing of the

present statement. The listed document could not have been submitted before publication.

No fees should be due in connection with the filing of this Supplemental Information

Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed

necessary for any reason, the Examiner should contact the undersigned representative to discuss

deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002587.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

10333 Richmond, Suite 1100 Houston, Texas, 77042

(713) 934-4079

Date: October 26, 2004

2

	•			PE						Page 1 of 1	
Form PTO-1449 (modified) OCT 2 9 2004						Atty. Docket No. 3999.002587			Serial No. 10/738,404		
List of Patents and Publications for Applicant						Applicant Thorpe and Brekken					
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)						Filing Date: December 17, 2003			Group: 1642		
U.S. Patent Documents See Page Foreign							ocuments	Other Art See Page 1			
	500 1			U.S. P	ater	nt Do	cuments				
Exam.			Document Number		Date		Name	Class	Sub Class	Filing Date of App.	
Init. Des.											
			F	oreign	Pa	tent	Document			Tuesdation	
Exam. Ref. Init. Des.		Document Number		Dat		e 	Country	Class	Sub Class	Translation Yes/No	
	Other A	Art (Ind	cludir	ng Aut	hor,	Title	e, Date Pe	rtinent	Pages,	Etc.)	
Exam. Init.	Ref. Des.						Citation				
	C164	Stephan et al., "Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer," Clin. Can. Res., 10:6993-7000, 2004.									

EXAMINER:

DATE CONSIDERED: